IM Cannabis (NASDAQ:IMCC – Get Free Report) and Talphera (NASDAQ:TLPH – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, valuation, risk and analyst recommendations.
Profitability
This table compares IM Cannabis and Talphera’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| IM Cannabis | -39.62% | N/A | -58.32% |
| Talphera | N/A | -87.28% | -51.36% |
Earnings and Valuation
This table compares IM Cannabis and Talphera”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| IM Cannabis | $45.80 million | 0.03 | -$8.10 million | ($60.66) | -0.02 |
| Talphera | $30,000.00 | 1,851.46 | -$14.29 million | ($0.27) | -3.96 |
IM Cannabis has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than IM Cannabis, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
7.7% of IM Cannabis shares are held by institutional investors. Comparatively, 37.7% of Talphera shares are held by institutional investors. 3.5% of Talphera shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of recent ratings and price targets for IM Cannabis and Talphera, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| IM Cannabis | 1 | 0 | 0 | 0 | 1.00 |
| Talphera | 1 | 1 | 2 | 0 | 2.25 |
Talphera has a consensus target price of $3.00, suggesting a potential upside of 180.37%. Given Talphera’s stronger consensus rating and higher possible upside, analysts clearly believe Talphera is more favorable than IM Cannabis.
Risk & Volatility
IM Cannabis has a beta of 2.21, meaning that its share price is 121% more volatile than the S&P 500. Comparatively, Talphera has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500.
Summary
Talphera beats IM Cannabis on 9 of the 14 factors compared between the two stocks.
About IM Cannabis
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.
About Talphera
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
Receive News & Ratings for IM Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IM Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.
